Q-omics provides the consensus-scored MTRNR2L13 profile across patient tissues and cancer cell-line models. MTRNR2L13 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L13 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MTRNR2L13 RNA expression shows 8,892 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CHOL, COAD, and ACC as cancer lineages where MTRNR2L13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L13 survival associations across molecular data types. MTRNR2L13 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L13 RNA expression–survival associations across cancer types. High MTRNR2L13 expression shows unfavorable associations in CHOL, UCEC, UCS and READ, but favorable associations in LIHC and PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MTRNR2L13 RNA expression.
This table summarizes MTRNR2L13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L13 shows lower tumor expression in COAD, ESCA, THCA and LIHC and higher tumor expression in LUAD and KICH. The COAD box plot shows higher MTRNR2L13 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .014).
This table shows molecular features associated with MTRNR2L13 in patient tissues and cancer cell lines. In patient samples, MTRNR2L13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
